Press Release

Printer Friendly Version View printer-friendly version
<< Back
GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the H.C. Wainwright Global Life Sciences Conference in Monte Carlo, Monaco on Tuesday, April 10 at 9:00 a.m. Central European Time.

The presentation will be webcast live and available for replay from GBT’s website at in the Investors section.

About GBT
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit and follow the company on Twitter @GBT_news.

Contact Information:
Myesha Lacy (investors)

Julie Normart (media)
W2O pure

Primary Logo

Global Blood Therapeutics, Inc.